Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal. All content is subject to the portal’s Community Content Guidelines.
What FDA's INTERACT Feedback Means for the CMC Pathway
FDA's written INTERACT feedback (following the July 16 meeting) noted our nonclinical data support a proposed early, exploratory clinical study, recommended plasma lyso-Gb3 as the primary pharmacodynamic readout, endorsed at least two years of eGFR follow-up, and confirmed CMC knowledge (vector backbone, packaging system, process steps) can be leveraged across Glafabra's Fabry, Pompe, and Gaucher ...more
The Clinical Data Dilemma: Balancing Speed and Credibility in Communicating Early-Stage Life Science Clinical Results
Prepared by Putnam Insights LLC
For any early-stage bio- or med-tech company, the arrival of initial positive clinical data presents an immediate dual challenge.
First, there is the fundamental need to establish a highly credible, enduring platform for your science. To gain traction with medical opinion leaders and regulatory bodies, the data must eventually live in a respected, peer-reviewed medi...more
What 'Testing the Waters' Actually Means
Testing the Waters is a formal SEC mechanism under Regulation Crowdfunding that lets a company gauge investor interest before filing a formal offering statement (Form C). No money can be solicited or accepted at this stage, and no offer to buy securities can be made.
That's why every post here carries the full disclosure below, and why registering interest is non-binding -- it's a real, if informa...more
What the Five-Year FACTS Data Does — and Does Not — Show
In the FACTS trial (5 patients, Canada, NCT02800070): a 48% reduction in plasma lyso-Gb3 vs. no-ERT baseline (p<0.0001) at 5-year follow-up; 4 of 5 patients below the lyso-Gb3 threshold at year 5; all 5 maintained durable enzyme expression; zero product-attributable serious adverse events; polyclonal integration with no clonal dominance.
This shows the approach can produce a durable biomarker r...more
What Changed After the First Two Campaign Months
Two months of daily public content. Here's the honest read.
Engagement grew meaningfully once we started introducing the team behind Live-cel and reacting to real industry news, rather than only running scheduled educational content. Our DECODE education series also moved from a manual answer-in-comments format to an integrated Q&A format, based on direct reader feedback.
None of this changes ...more
Two Months, One Platform, Three Diseases: Glafabra's Progress So Far
Two months. One platform. Three diseases. Building in public the whole way.
Fabry, Pompe, and Gaucher disease — three diseases the platform is designed to address by correcting one cell type and swapping in the disease-specific gene. An FDA meeting behind us, an IND protocol taking shape, University of Utah Health planned as the clinical site, and a Japan strategy running in parallel from day one.
...moreTwo Months Into Testing the Waters: What's Ahead for Glafabra
Two months of Testing the Waters, almost to the day.
Since June 22: 18 questions answered through DECODE, four members of the Glafabra team introduced in person on LinkedIn, and a real-time record of an FDA meeting, a protocol taking shape, and a Japan strategy moving in parallel with the U.S. one.
What's ahead: more team introductions, continued DECODE questions, and whatever comes out of IFFD an...more
How Common Is Fabry Disease? — DECODE No. 18
(Answer to the question last time on August 31: hands and feet — acroparesthesia, caused by small-fiber nerve involvement, often starting in childhood.)
Fabry disease is rare, but estimates for exactly how rare span a wide range — and most researchers think the real number is higher than any of them.
Roughly how many people are estimated to be born with Fabry disease? Drop your guess in the commen...more
